MRSN Quote, Financials, Valuation and Earnings

Climb Bio has a net margin of -86.29% compared to Mersana Therapeutics's net margin of --. Mersana Therapeutics's return on equity of -533.43% beat Climb Bio's return on equity of --.

Mersana Therapeutics has a consensus price target of $4.71, signalling upside risk potential of 1201.21%. On the other hand Climb Bio has an analysts' consensus of $10.00 which suggests that it could grow by 669.23%. Given that Mersana Therapeutics has higher upside potential than Climb Bio, analysts believe Mersana Therapeutics is more attractive than Climb Bio.

Mersana Therapeutics has a beta of 1.683, which suggesting that the stock is 68.275% more volatile than S&P 500. In comparison Climb Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Climb Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Climb Bio pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $16.4M, which are larger than Climb Bio quarterly revenues of --. Mersana Therapeutics's net income of -$14.1M is lower than Climb Bio's net income of -$8.4M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Climb Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.10x versus -- for Climb Bio. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology has a net margin of -86.29% compared to Mersana Therapeutics's net margin of -20.17%. Mersana Therapeutics's return on equity of -533.43% beat Pyxis Oncology's return on equity of --.

Mersana Therapeutics has a consensus price target of $4.71, signalling upside risk potential of 1201.21%. On the other hand Pyxis Oncology has an analysts' consensus of $6.00 which suggests that it could grow by 450.46%. Given that Mersana Therapeutics has higher upside potential than Pyxis Oncology, analysts believe Mersana Therapeutics is more attractive than Pyxis Oncology.

Mersana Therapeutics has a beta of 1.683, which suggesting that the stock is 68.275% more volatile than S&P 500. In comparison Pyxis Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Pyxis Oncology pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $16.4M, which are larger than Pyxis Oncology quarterly revenues of $16.1M. Mersana Therapeutics's net income of -$14.1M is higher than Pyxis Oncology's net income of -$35.6M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Pyxis Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.10x versus -- for Pyxis Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -86.29% compared to Mersana Therapeutics's net margin of -489.18%. Mersana Therapeutics's return on equity of -533.43% beat Sutro Biopharma's return on equity of -204.67%.

Mersana Therapeutics has a consensus price target of $4.71, signalling upside risk potential of 1201.21%. On the other hand Sutro Biopharma has an analysts' consensus of $3.43 which suggests that it could grow by 163.74%. Given that Mersana Therapeutics has higher upside potential than Sutro Biopharma, analysts believe Mersana Therapeutics is more attractive than Sutro Biopharma.

Mersana Therapeutics has a beta of 1.683, which suggesting that the stock is 68.275% more volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.657%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $16.4M, which are larger than Sutro Biopharma quarterly revenues of $14.8M. Mersana Therapeutics's net income of -$14.1M is higher than Sutro Biopharma's net income of -$72.4M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.10x versus 1.61x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -86.29% compared to Mersana Therapeutics's net margin of -549.33%. Mersana Therapeutics's return on equity of -533.43% beat Voyager Therapeutics's return on equity of -21.07%.

Mersana Therapeutics has a consensus price target of $4.71, signalling upside risk potential of 1201.21%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 356.09%. Given that Mersana Therapeutics has higher upside potential than Voyager Therapeutics, analysts believe Mersana Therapeutics is more attractive than Voyager Therapeutics.

Mersana Therapeutics has a beta of 1.683, which suggesting that the stock is 68.275% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.773%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $16.4M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. Mersana Therapeutics's net income of -$14.1M is higher than Voyager Therapeutics's net income of -$34.5M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.10x versus 2.54x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.